This Penny Stock Touts Encouraging Long-Term Data For Hemophilia Gene Therapy

Small biotech Freeline Therapeutics Holdings plc FRLN hopes new long-term data will help boost its case.
The company announced that the New England Journal of Medicine (NEJM) published positive data, expanding upon previously announced long-term follow-up data for up to 3.5 years from the Phase 1/2 B-AMAZE trial of hemophilia B gene therapy candidate, FLT180a.
Hemophilia is an inherited bleeding disorder caused by a deficiency in coagulation factor IX (FIX).
Related: Freeline Posts Cases Of Lower FIX Expression, Higher Liver Enzymes From Hemophilia Candidate.
Nine of 10 patients maintained their factor IX activity at a median follow-up of 27.2 months, with one patient seeing a response as far out as 42.4 months. Researchers published their findings in the New England Journal of Medicine.
Freeline’s study also saw one patient with the highest factor IX levels experienced a severe adverse event of arteriovenous fistula thrombosis.
The company said that enrollment in Phase 1/2 B-LIEVE dose confirmation trial will conclude by the end of Q3 enabling pivotal Phase 3 start-up activities in 1H of 2023.
Price Action: FRLN shares are down 1.54% at $0.76 during the market session on the last check Thursday.